EP4704837A2 - Verfahren zur verwendung von bakterien und wirts-/mikrobiota-abgeleiteten metaboliten zur diagnose und behandlung von endometriose - Google Patents
Verfahren zur verwendung von bakterien und wirts-/mikrobiota-abgeleiteten metaboliten zur diagnose und behandlung von endometrioseInfo
- Publication number
- EP4704837A2 EP4704837A2 EP24804042.0A EP24804042A EP4704837A2 EP 4704837 A2 EP4704837 A2 EP 4704837A2 EP 24804042 A EP24804042 A EP 24804042A EP 4704837 A2 EP4704837 A2 EP 4704837A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- bacteria
- indole
- metabolites
- individual
- metabolite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363500476P | 2023-05-05 | 2023-05-05 | |
| PCT/US2024/027820 WO2024233382A2 (en) | 2023-05-05 | 2024-05-03 | Methods for using bacteria and host/microbiota-derived metabolites for diagnosis and treatment of endometriosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4704837A2 true EP4704837A2 (de) | 2026-03-11 |
Family
ID=93431058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24804042.0A Pending EP4704837A2 (de) | 2023-05-05 | 2024-05-03 | Verfahren zur verwendung von bakterien und wirts-/mikrobiota-abgeleiteten metaboliten zur diagnose und behandlung von endometriose |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP4704837A2 (de) |
| WO (1) | WO2024233382A2 (de) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9981959B2 (en) * | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
-
2024
- 2024-05-03 WO PCT/US2024/027820 patent/WO2024233382A2/en not_active Ceased
- 2024-05-03 EP EP24804042.0A patent/EP4704837A2/de active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024233382A3 (en) | 2025-04-03 |
| WO2024233382A2 (en) | 2024-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200377945A1 (en) | Biomarkers for type 2 diabetes mellitus and use thereof | |
| US12285475B2 (en) | Bacterium capable of inducing TH1 cells | |
| JP2020516585A (ja) | 安定性の高いマンガンスーパーオキシドジスムターゼの使用 | |
| KR20250155052A (ko) | 장내 미생물총 개체군 조절, 장내 미생물 불균형의 치료 및 질환 예방을 위한 조성물, 및 이의 제조 및 사용 방법 | |
| CN120818452A (zh) | 鼠李糖乳酪杆菌在制备防治炎症性肠病产品中的用途 | |
| CN111304120B (zh) | Blautia sp B2132菌在预防和/或治疗炎症性肠病中的应用 | |
| WO2019157566A1 (en) | Compositions and methods for promoting gut health | |
| EP4704837A2 (de) | Verfahren zur verwendung von bakterien und wirts-/mikrobiota-abgeleiteten metaboliten zur diagnose und behandlung von endometriose | |
| US20210247394A1 (en) | Isolated bacterial strain for inducing proliferation or accumulation of regulatory t-cells | |
| WO2021191312A1 (en) | Methods of treating covid-19 with rifaximin | |
| Cho et al. | Live Malassezia strains from the mucosa of patients with ulcerative colitis: pathogenic potential and environmental adaptations | |
| WO2016044578A1 (en) | Antifungal therapy for the treatment of hirschsprung-associated enterocolitis | |
| CN113308416B (zh) | 一株具有抑制肾结石形成能力的植物乳杆菌及其应用 | |
| WO2023076874A1 (en) | Methods and composition for the treatment of prader-willi syndrome symptoms | |
| EP4426324A1 (de) | Verfahren und zusammensetzungen zur vorhersage des überlebens von krebs und der toxizität von car-t-zellen | |
| WO2023080154A1 (ja) | 有害事象リスクの判定方法 | |
| CN115919953A (zh) | 一种改善高尿酸血症的组合物及其应用 | |
| CN109718254B (zh) | 颤杆菌克属在预防或治疗高原病药物中的应用 | |
| CN116042875A (zh) | 一种用于预警ⅱ型糖尿病发生的微生物标志物及其应用 | |
| US20240350563A1 (en) | Biotherapeutic enterococcus isolates | |
| Martínez-Hernandez et al. | Pyogenic liver abscess caused by an atypical hypervirulent Klebsiella pneumoniae K1-ST23 in Mexico | |
| WO2019235447A1 (ja) | 糖尿病誘起細菌 | |
| Lai et al. | Genomic, virulent and phenotypic characterization of a cerebrospinal fluid-derived ST86-KL2 hypervirulent Klebsiella pneumoniae isolate from a patient with meningitis and diabetes mellitus | |
| US20250186470A1 (en) | Compositions and Methods Using Lactulose for Treating Disease | |
| AU2021353115A1 (en) | Therapeutic bacterial composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20251119 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |